All News

Malar Rash and Polyarthritis

d Jack Cush, MD

58-year-old woman with a history of hypothyroidism presents with a 2-week history of joint pain and swelling in her right knee, which became migratory and later affected the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joints of her fingers; this followed a series of others being sick in the household.

Read Article
RN.podcast.resized.jpg

RheumNow Podcast – FDA Panels Meet on Gout & OP (1.18.19)

d Jack Cush, MD

Dr. Jack Cush reviews the news, articles and FDA Panel discussions from the past week.

Read Article
GCA temporal artery

Does Methotrexate Work in Giant Cell Arteritis?

d Jack Cush, MD

There seems to be both hope and uncertainty regarding the use of weekly methotrexate (MTX) in giant cell arteritis (GCA) patients whom need to limit their glucocorticoid use.

Read Article
OP.risk_.jpg

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

d Jack Cush, MD

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Read Article
injection_1.jpg

Anakinra for Acute Crystal-Induced Arthritis

d Jack Cush, MD

A retrospective analysis of hospitalized patients who also had a gout and pseudogout attack shows that injections of anakinra (interleukin-1 receptor antagonist) were highly effective and safe in nearly three-quarters of patients.  

Read Article
FDA.panel_.jpg (keep)

Febuxostat Gets Reprieve from FDA Advisory Panel

d Jack Cush, MD

On January 11, 2019 the FDA convened two advisory panels (the Arthritis Advisory Committee [AAC] and the Drug Safety and Risk Management Advisory Committee [DSaRM]) to consider the cardiovascular safety of febuxostat (Uloric) based on the 2018 “Cardiovascular Safety of Febuxostat and Allopurinol

Read Article
JAMA study shows that when drug companies increased their opioid marketing budgets by just $5.29 per 1,000 population, the number of MD opioid prescriptions went up 82% and opioid deaths increased 9%. https://t.co/4FAr53gH17

Links:

Dr. John Cush RheumNow ( View Tweet)

"Teach what you most need to learn" - Tony Robbins

Dr. John Cush RheumNow ( View Tweet)

The Weekly RheumNow Podcast is up - FDA hearings, anakinra in crystal arthritis, SSc renal crisis predictors & lower mortality in lupus nephritis. Watch here https://t.co/Ph5IK9syqw or listen at iTunes or here https://t.co/EVBAszEb9J

Links:

Dr. John Cush RheumNow ( View Tweet)

For what reason have you "fired" or discharged a patient from your clinic

Dr. John Cush RheumNow ( View Tweet)

Curious, mind-bending Rheumatologists who like to teach....go to https://t.co/4UQlqwujiR

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC reports that opioid overdoses are more likely to kill Americans than car crashes. Themotor vehicle death rate =11.5 per 100,000 in 2017 (use to be 15.2) vs opioid overdose deaths of 14.9 per 100,000 in 2017 (up from 2.9 in 1999). https://t.co/n8cFgvKyGu

Links:

Dr. John Cush RheumNow ( View Tweet)

CARRA legacy registry of 631 pts with Juvenile Dermatomyositis finds 13% with current or past calcinosis; Calcinosis was associated with longer durations of disease prior to Dx, lipodystrophy, joint contractures, and treatment with IVIG or RTX https://t.co/x8NstBdptc.

Links:

Dr. John Cush RheumNow ( View Tweet)

For what reason have you "fired" or discharged a patient from your clinic

Dr. John Cush RheumNow ( View Tweet)

A scleroderma/Raynauds patient just showed us her favorite XMAS gift - an Electric Hand Warmer - you can buy these on Amazon for $15-30. Very Cool!! https://t.co/My06QzcHhj
Dr. John Cush RheumNow ( View Tweet)
Contraceptive surveys of 164 arthritis pts(138 Rheumatoid;26 Psoriatic) finds one-third (32-35%) using highly effective contraception; 31% using effective methods; but ineffective methods in 35.5% RA & 11.5% PsA and no contraception in 1.5% RA & 23.1% PsA https://t.co/gGBtL2z1FK

Links:

Dr. John Cush RheumNow ( View Tweet)

Outside of work, rheumatologists are the happiest... what about while working? https://t.co/rnVWiXSx1f

Links:

Dr. Rachel Tate uptoTate ( View Tweet)

Who thought this was possible? Numbers suggest this is rare. Tis wrong to use this to forge ahead with an unlikely PMR dx in the face of a normal CRP/ESR; but will you go so far as to order the expensive FDG-PET? https://t.co/RTkiUXO7lX

Links:

Dr. John Cush RheumNow ( View Tweet)

Vote now on this: https://t.co/j2Dfjdpuat

Links:

Dr. John Cush RheumNow ( View Tweet)

Today Jan 16th the FDA advisory comm will review the CV safety of anti-sclerostin drug Evenity (romosozumab). July 2018 the FDA issued a complete response letter for CV safety concerns. Amgen seeks indication for use in postmenopausal osteoporosis. https://t.co/IRr1nKJ43s

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×